News | PET Imaging | April 19, 2021

Study continues with rheumatoid arthritis patients

The inflamed joints of a #rheumatoid #arthritis patient are clearly visible in the #PET images with the novel 68Ga-DOTA-Siglec-9 #radiopharmaceutical. Image courtesy of Anne Roivainen

The inflamed joints of a rheumatoid arthritis patient are clearly visible in the PET images with the novel 68Ga-DOTA-Siglec-9 radiopharmaceutical. Image courtesy of Anne Roivainen


April 19, 2021 — The preliminary trial results of a novel radiopharmaceutical for PET imaging of inflammation developed at the University of Turku, Finland, have been published. The compound, which targets the vascular adhesion protein 1 (VAP-1) that regulates inflammatory cell traffic, is the first radiopharmaceutical that has been developed completely in Finland and has advanced to clinical trials. In the study that started with healthy volunteers, the radiopharmaceutical was found to be well tolerated and safe.

The radiopharmaceutical is 68Ga-labelled Siglec-9 peptide.

"The dose of the radiopharmaceutical used in PET imaging is thousands of times lower when compared with the regular drugs. Studies with new radiopharmaceuticals are therefore safer than the usual drug research studies," explained Researchers Riikka Viitanen and Olli Moisio from the Turku PET Centre.

The study also included the imaging of a patient with early rheumatoid arthritis. The inflamed joints were clearly visible in the PET images, and the radiopharmaceutical seems to effectively target inflamed tissue.

"Our radiopharmaceutical is a product of long-term preclinical research work, and it is rewarding to see results that match our expectations. The research results are promising, but all novel radiopharmaceuticals must fulfil strict medical and statistical criteria before they can be considered for general research use. Therefore, we will continue the study with voluntary rheumatoid arthritis patients," says the leader of the research group, Professor Anne Roivainen from the University of Turku.

"This study is unique and has long, innovative history in the University of Turku. Now, it has been proven that the new radiopharmaceutical works in humans," said Academician of Science Professor Sirpa Jalkanen.

The purpose of the new radiopharmaceutical is to advance both the diagnostics of inflammatory diseases and drug development with molecular imaging. The research field is rapidly developing, and the Turku PET Centre, research institute of the University of Turku, Åbo Akademi University, and Turku University Hospital is one of the field's leading research centres in Europe.

For more information: www.utu.fi/en/ 

Related Content

News | Proton Therapy

August 19, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time August 19, 2022
arrow
News | SNMMI

August 16, 2022 — Mike Crosby of San Diego, California, has been elected to a two-year term as vice chair of the Patient ...

Time August 16, 2022
arrow
Feature | Magnetic Resonance Imaging (MRI) | Christine Book

August 10, 2022 — The imaging community has lost a legend, recognized for having revolutionized the field of diagnostic ...

Time August 10, 2022
arrow
News | Nuclear Imaging

July 27, 2022 — Patients for Safer Nuclear Medicine, a coalition of 29 patient advocacy organizations representing ...

Time July 27, 2022
arrow
News | Breast Imaging

July 21, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), understanding the likelihood of malignancy ...

Time July 22, 2022
arrow
News | Radiopharmaceuticals and Tracers

July 20, 2022 — -NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time July 20, 2022
arrow
News | PET Imaging

July 19, 2022 — Radialis Inc. today announced that it has received clearance to market the Radialis PET Imager, an organ ...

Time July 19, 2022
arrow
News | Contrast Media

July 18, 2022 — Fresenius Kabi announced today it will introduce a portfolio of generic contrast media agents in the ...

Time July 18, 2022
arrow
News | Molecular Imaging

July 11, 2022 — The "Molecular Imaging Market, by Application (Cancer, Heart Disease, Brain Disorder), by Technology ...

Time July 12, 2022
arrow
News | PET-CT

July 11, 2022 – The American Society of Nuclear Cardiology (ASNC) and the Society of Nuclear Medicine and Molecular ...

Time July 11, 2022
arrow
Subscribe Now